https://oncodaily.com/insight/211553

On Day 1 of 2025 want to thank @oncodaily for shout out & share their post. While early, this is promising news for patients with head & neck #cancer #HNSCC /lots of people responsible Drs. Rom Leidner @rbryanbell.bsky.social @walterurba.bsky.social #FinishCancer #UbiVac #Incyte
t.co/bO0JC32H5A

#Bridge2024 coming to a close! Saturday, December 7th 2024 @2:10 pm and we are entering the last session/will cover 1st line #immunotherapy, salvage, igniting change in #cancer #vaccine development, combo IO, #PD1 refractory & more @sitcancer.bsky.social #MSD #BIOTECH #BMS #Merck #Regeneron #UbiVac

Clinical Studies - UW Veterinary CareSite iconsMoreopen menuclosesearchsearchsearchenvelopepinterest-ptwitteryoutubefacebookinstagramCollapseExpandnext slideprevious slideFooter Crest UV Veterinary Care has clinical studies in cardiology, genetics, neurology, oncology, and ophthalmology for dogs, cats, rabbits, and horses.

@truebuddhism.bsky.social Treatment trials for #GoldenRetrievers & other #CompanionAnimals incl w/ #immunotherapy & #radiationtherapy are avail/Possible #vaccine 2 prevent cancer in #dogs? #UbiVac thinks so! #FinishCancer #SethPollackLab @NWU + @UWI / uwveterinarycare.wisc.edu/veterinary-c...

Clinical Studies in Oncology - UW Veterinary CareSite iconsMoreopen menuclosesearchsearchsearchenvelopepinterest-ptwitteryoutubefacebookinstagramCollapseExpandnext slideprevious slideFooter Crest

@truebuddhism.bsky.social Treatment trials for #GoldenRetrievers & other #CompanionAnimals incl w/ #immunotherapy & #radiationtherapy are avail/Possible #vaccine 2 prevent cancer in #dogs? #UbiVac thinks so! #FinishCancer #SethPollackLab @NWU + @UWI / uwveterinarycare.wisc.edu/veterinary-c...

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer | NEJM Patients with microsatellite-instability–high (MSI-H) or mismatch-repair–deficient (dMMR) metastatic colorectal cancer have poor outcomes with standard chemotherapy with or without targeted therapi...

💥Yesterday #NEJM: Phase 3 randomized trial for metastatic MSI-H #colorectal #cancer /24-month progression-free survival (PFS) of 72% for #immunotherapy (IPI/NIVO) compared to 14% for #chemotherapy /Next? Vaccines 2 induce T cells to #MSS #DarkMatter #antigens #UbiVac
www.nejm.org/doi/full/10....